141 related articles for article (PubMed ID: 9359521)
1. The effects of anagrelide on human megakaryocytopoiesis.
Solberg LA; Tefferi A; Oles KJ; Tarach JS; Petitt RM; Forstrom LA; Silverstein MN
Br J Haematol; 1997 Oct; 99(1):174-80. PubMed ID: 9359521
[TBL] [Abstract][Full Text] [Related]
2. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia.
Tomer A
Blood; 2002 Mar; 99(5):1602-9. PubMed ID: 11861274
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the biological activities of anagrelide and its major metabolites in haematopoietic cell cultures.
Wang G; Franklin R; Hong Y; Erusalimsky JD
Br J Pharmacol; 2005 Oct; 146(3):324-32. PubMed ID: 16041400
[TBL] [Abstract][Full Text] [Related]
4. Anagrelide is an anti-megakaryocytic and not an anti-platelet agent.
Watson SP; Dalby A
Platelets; 2019; 30(1):136-137. PubMed ID: 30404556
[No Abstract] [Full Text] [Related]
5. Anagrelide platelet-lowering effect is due to inhibition of both megakaryocyte maturation and proplatelet formation: insight into potential mechanisms.
Espasandin YR; Glembotsky AC; Grodzielski M; Lev PR; Goette NP; Molinas FC; Marta RF; Heller PG
J Thromb Haemost; 2015 Apr; 13(4):631-42. PubMed ID: 25604267
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans.
Mazur EM; Rosmarin AG; Sohl PA; Newton JL; Narendran A
Blood; 1992 Apr; 79(8):1931-7. PubMed ID: 1562721
[TBL] [Abstract][Full Text] [Related]
7. Anagrelide represses GATA-1 and FOG-1 expression without interfering with thrombopoietin receptor signal transduction.
Ahluwalia M; Donovan H; Singh N; Butcher L; Erusalimsky JD
J Thromb Haemost; 2010 Oct; 8(10):2252-61. PubMed ID: 20586925
[TBL] [Abstract][Full Text] [Related]
8. Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation.
Lane WJ; Hattori K; Dias S; Peerschke EI; Moore MA; Blanset DL; Lang PC; Petrone M; Rafii S
Exp Hematol; 2001 Dec; 29(12):1417-24. PubMed ID: 11750100
[TBL] [Abstract][Full Text] [Related]
9. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. an immunohistochemical and morphometric study of sequential trephine biopsies.
Thiele J; Kvasnicka HM; Fuchs N; Brunnbauer K; Volkwein N; Schmitt-Graeff A
Haematologica; 2003 Oct; 88(10):1130-8. PubMed ID: 14555309
[TBL] [Abstract][Full Text] [Related]
10. [Anagrelide--new antiplatelet drug].
Robak T; Treliński J; Hołub A
Acta Haematol Pol; 1994; 25(4):309-15. PubMed ID: 7847031
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of human primary megakaryocyte differentiation by anagrelide: a gene expression profiling analysis.
Sakurai K; Fujiwara T; Hasegawa S; Okitsu Y; Fukuhara N; Onishi Y; Yamada-Fujiwara M; Ichinohasama R; Harigae H
Int J Hematol; 2016 Aug; 104(2):190-9. PubMed ID: 27084257
[TBL] [Abstract][Full Text] [Related]
12. Comparison between anagrelide and hydroxycarbamide in their activities against haematopoietic progenitor cell growth and differentiation: selectivity of anagrelide for the megakaryocytic lineage.
Hong Y; Wang G; Del Arroyo AG; Hernandez J; Skene C; Erusalimsky JD
Leukemia; 2006 Jun; 20(6):1117-22. PubMed ID: 16557242
[TBL] [Abstract][Full Text] [Related]
13. Anti-platelet drugs: do they affect megakaryocytes?
Cazenave JP; Gachet C
Baillieres Clin Haematol; 1997 Feb; 10(1):163-80. PubMed ID: 9154321
[TBL] [Abstract][Full Text] [Related]
14. Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5,6-dichloro-3,4-dihydroquinazoline (RL603)?
Erusalimsky JD; Hong Y; Franklin R
Exp Hematol; 2002 Jul; 30(7):625-6; author reply 626-7. PubMed ID: 12135656
[No Abstract] [Full Text] [Related]
15. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia.
Yoon SY; Li CY; Mesa RA; Tefferi A
Br J Haematol; 1999 Sep; 106(3):682-8. PubMed ID: 10468856
[TBL] [Abstract][Full Text] [Related]
16. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders.
Balduini CL; Bertolino G; Noris P; Ascari E
Haematologica; 1992; 77(1):40-3. PubMed ID: 1398280
[TBL] [Abstract][Full Text] [Related]
17. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indications.
Tefferi A; Silverstein MN; Petitt RM; Mesa RA; Solberg LA
Semin Thromb Hemost; 1997; 23(4):379-83. PubMed ID: 9263355
[TBL] [Abstract][Full Text] [Related]
18. Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia.
Spencer CM; Brogden RN
Drugs; 1994 May; 47(5):809-22. PubMed ID: 7520859
[TBL] [Abstract][Full Text] [Related]
19. Anagrelide: what was new in 2004 and 2005?
Petrides PE
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615
[TBL] [Abstract][Full Text] [Related]
20. Effects of anagrelide on platelet cAMP levels, cAMP-dependent protein kinase and thrombin-induced Ca++ fluxes.
Seiler S; Arnold AJ; Grove RI; Fifer CA; Keely SL; Stanton HC
J Pharmacol Exp Ther; 1987 Nov; 243(2):767-74. PubMed ID: 2824759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
